conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research feb
estim feb
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
narrow moat stem domin essenti
posit within dialysi market account one
third dialysi facil patient treatment
much investor concern last year ultim
stem industri structur levi industrywid profit
small hand commerci insur patient caution
investor lose sight bigger pictur provid
lifesav healthcar servic chronic ill patient
lower-cost outpati set sinc altern outpati
dialysi higher cost less effici burdensom acut
therapi see littl likelihood falter due regulatori
disrupt long term said think continu
scrutini patient assist program could caus near-term pain
industri propos legisl goe effect limit
patient abil continu commerci plan time
howev
consolid leav compar advantag posit
versu smaller independ peer lack cost advantag
present oper think investor need balanc
consider risk industri compel
volum growth
low-
would catalyz
valuat summari forecast
financi summari forecast
put asid present concern industri take
favor view manag recent sale davita
medic group asset long drag profit return
capit busi perenni under-perform follow
acquisit absent major structur chang dialysi
reimburs polici anticip return capit
improv manag focus scale intern
presenc without distract dmg assess
manag capit alloc prowess somewhat
tarnish experi dmg plan use
billion proce larg debt reduct stepped-up share
repurchas like near immedi value-cr capit
historical/forecast data sourc morningstar estim may reflect adjust
davita inc largest provid dialysi servic boast
market share level eclips measur patient clinic
firm oper facil world-wide locat
unit state treat patient global year
manag began build fledgl intern busi
anticip busi need continu expand
garner scale need earn attract return govern payer
domin dialysi reimburs -- receiv approxim
 sale medicar medicaid reimburs rate
remain come commerci insur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
slightli lower fair valu estim per
share reflect modestli lower cash flow
forecast incorpor revis billion sale price
dmg impli time updat
estim adjust earn ebitda respect
forecast call growth domest
dialysi servic oper contempl treatment
growth near revenu per treatment
approxim five-year forecast horizon
volum assumpt impli modest share gain
period gain roughli basi point
share patient given matur
segment think increment margin gain difficult
come model less basi point total
margin expans forecast period importantli
assum materi profit impact on-going
concern regard premium assist across industri
legisl propos ballot initi california
fail garner broad-bas support result
risk cash flow appear retreat
surpris ultim last
regulatori effort target dialysi industri
firm intern dialysi busi estim
revenu growth nearer low- mid-teen rate
forecast period manag focus invest
segment driven double-digit growth total
number clinic oper annual price
improv averag time busi
gain scale estim meaning improv
profit break-even slightli profit level
forecast ebitda margin roughli
believ ampl room exist continu expans
matur level like low- mid-teen
although expos sizabl low-prob risk
view think share deserv medium
bull-cas scenario think firm consolid
revenu grow roughli approxim basi
point better base-cas estim help
treatment growth nearer better
price environ lead growth annual
per-treat price averag forecast period
addit aggress
intern market lead high-teen growth revenu
growth rate segment faster growth less
restrict price environ allow better-than-expect
margin perform estim nearli basi
point oper ebitda margin expans
firm domest dialysi segment bull-cas
assumpt lead consolid oper
margin roughli near histor high
busi incorpor assumpt result
fair valu estim per share time
higher estim earn ebitda
bear-cas assumpt result total compani revenu
growth nearer basi point lower
base-cas forecast case expect firm
oper grow treatment volum line total esrd
patient growth flat overal per-treat price
perpetu incorpor modest impact
propos chang patient access
ebitda forecast roughli lower base case
estim price pressur cost inflat combin
reduc dialysi margin approxim basi
point intern segment lower level
invest new facil cost pressur result
modest profit low singl digit
lead total compani oper margin
histor low estim culmin fair valu
estim per share time lower
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
capac keep pace patient growth
also improv conveni number
facil unit state stood roughli
approxim compound annual
growth rate period estim
par overal growth rate preval end-stag
renal diseas esrd case sinc
like mani healthcar provid coverag
govern payer medicar medicaid
repres largest payer nation unlik
compani coverag esrd diseas state
automat qualifi
medicar coverag
regardless patient age circumst specif
patient tradit commerci insur allow
earli enrol medicar month initi
environ make negoti commerci
payer vastli import tradit healthcar
provid explain dialysi servic becom
highli concentr
fragment seen area acut care
aggreg govern reimburs estim
industri level must extract commerci
insur earn roughli two third revenu
government-bas payer third
commercial-pay patient said estim patient
mix even lopsid roughli patient
base commerci insur medicar per
treatment base payment rate estim
commerci reimburs fall north
abil earn reimburs rate nearli
time govern will pay indic
substanti negoti leverag view
cost side equat industri benefit
scale high capac util accord medpac
lowest volum facil oper medicar cost
earn ebitda estim respect
believ peer freseniu medic
benefit scale-deriv cost advantag thank
domin global dialysi market combin
estim two entiti account greater
dialysi market unit state measur
either clinic oper patient treat level
scale provid per-unit cost advantag firm
along materi negoti power contract
commerci insur crucial sustain
earn excess return industri
treat patient unit state
current requir mainten
although home-bas treatment exist
gain margin share time in-cent treatment
gruel requir three center visit per week hour
rest patient life receiv
kidney transplant result dialysi industri
continu expand overal facil count build
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
divestitur davita medic group believ core
element underpin firm cost advantag within
dialysi remain stabl time estim
firm continu grow share unit state
expand facil base addit break-even
intern busi like contribut
enterpris time achiev relev scale davita
better abl leverag invest made
to-dat reimburs uncertainti unlik
fade given dynam industri think davita
retain posit low end cost curv
key reduc cost improv outcom
treatment esrd
per treatment north highest volum
oper benefit cost closer
annual place estim averag cost medicar
patient somewher per treatment
help valid profit estim payer
suggest
medicar busi break-even best even largest
provid space freseniu oper
best-in-class util level help improv
unit econom -- two largest provid oper
roughli firm-wide capac averag versu
rest industri oper littl
view advantag two side scale
earn best-in-class reimburs
commerci insur also provid procur
effici support firm consist mid-teen
separ firm moat worthi dialysi franchis
process divest medic
group dmg busi unitedhealth group
close end year support
divestitur firm abl get favor
price asset billion versu billion paid
acquir think would deserv
no-moat rate best estim put dmg return
capit mid-single-digit rang declin
sinc initi bought busi think
addit asset one major factor
behind compani weaker return profil sinc
estim suggest return focu core dialysi
busi quickli improv futur return
expect firm profil improv follow
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
benefit long-term tailwind
grow global esrd patient popul
preval diabet hypertens continu
market-lead posit ensur
benefit low-cost oper industri
becom increasingli hostil sub-scal provid
ounderpenetr intern market quickli
becom largest esrd market world
oper allow continu growth
owith except high relianc commerci
reimburs profit industri would
neg impact insur gain addit
flexibl move patient book onto
oalthough medicar rate updat trend
posit late recent net payment
updat like still overal cost inflat
experienc servic provid
ochang govern polici regard attitud
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
think firm oper respons leverag
profil given high consist busi gross
debt level typic rang time adjust
ebitda howev given pend sale dmg
ebitda repurchas share favor price throughout
follow divestitur dmg expect
manag alloc roughli billion billion
cash proce toward debt reduct leav
leverag estim near time howev also note
leas nearli dialysi clinic creat
roughli billion estim reimburs
pressur pose acut risk dialysi provid unseen
elsewher healthcar provid sector given
industri relianc small segment overal esrd
patient popul maintain profit oper
remain key oper risk think
superior cost posit help insul advers
market condit compar smaller fragment
give medium uncertainti rate due
critic natur servic provid expand
patient popul firm concentr exposur
govern payer line peer unilater
reimburs pressur remain key risk
industri howev think firm substanti scale
ensur well posit mitig headwind
aris potenti reimburs cut reduc patient
coverag commerci insur time
face new risk potenti opportun expand
busi improv live patient broader
adopt comprehens care initi increas
quality-link payment penalti chang
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
busi model futur payment technolog
risk like gener headlin come year
hemodialysi primari treatment modal unlik
signific co-morbid within patient popul
skew older make widespread adopt home-bas
therapi difficult view said like gain
share margin technolog continu advanc
becom patient-friendli see
major risk core oper final
appeal court struck propos rulemak
center medicar medicaid servic relat
limit dialysi patient access premium assist
program recent propos legisl california
state threaten enact similar barrier patient
access specif initi fail gain
traction think like see futur propos
target dialysi industri given outsiz per-pati
cost structur probabl on-going risk
firm profit believ superior cost posit
allow weather upcom storm
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
share
fund
share
fund
give kent thiri rest manag team
davita standard mark capit stewardship
think team done except job develop
firm domin posit dialysi market
unit state think firm foray broader
purchas
healthcar partner rais red flag
year reimburs pressur leadership turnov
busi restructur happi see manag
enter agreement sell busi nearli
billion said fail invest coordin
care leav us skeptic relat futur capit
alloc manag intend use cash windfal
pay debt repurchas share two use capit
think benefit sharehold long run given
firm current market valuat go forward
interest manag invest prioriti without
distract dmg segment -- prefer see
bulk no-moat intern dialysi oper
make anoth attempt diversifi area
healthcar
fan compens structur put place
compani board believ well suit
hold manag account sharehold valu
creation manag annual bonu tie
clinic outcom oper incom
think critic measur success long-term
incent pay execut offic split
perform share time-bas award half tie
metric adjust earn rel total
sharehold return half subject
time-bas vest schedul said like see
insid ownership upper level manag
particularli given member long tenur firm --
whole director offic group less
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
report mix end valuat remain
narrow-moat report mix overal result
fiscal fourth quarter full year although balanc net
perform less line expect
firm dialysi busi met revenu
forecast fall slightli short outlook
profit account adjust model
like make modest chang
per share fair valu estim impli time
time lower adjust earn ebitda
forecast current market price suggest
multipl nearer respect given
strike valuat disconnect remain top pick
healthcar coverag boast rate
upsid fair valu
manag provid guidanc call oper
incom billion billion impli
mid-single-digit growth midpoint anticip
better number given mani one-off occur
expect rang prove conserv --
estim remain high end said organ
treatment growth report fourth quarter
uncharacterist weak undeni concern
three quarter growth averag fourth quarter
came mark lowest quarterli organ
rate last decad manag maintain
expect disappoint
full-year number project call
compound annual rate continu
below-trend treatment growth potenti higher
patient advocaci cost like two main risk
project year ahead
off-set lower capit spend need buoy free
cash flow time combin increas home
therapi penetr potenti lower volum growth
requir fewer clinic open improv firm
unfortun appear dialysi industri
pit california legislatur year
may result higher advocaci spend need
increment million embed manag
outlook last month california assembl introduc ab
less rehash ab
pass subsequ veto last year short bill
would effect cap reimburs rate small
number commerci insur patient receiv third-
parti financi assist prevail medicar payment
due concern around patient access manag
quantifi potenti impact propos
million million hit oper incom
favor prior estim million
million reduct profit like attribut cost-
save measur potenti facil closur pleas see
regulatori concern addit background
california dialysis-rel polici propos last year
despit concern think structur
dialysi industri set improv come five year
medicar payment rate updat turn posit
five year rate rebas
reimburs flat period patient
allow enrol medicar advantag plan begin
help price provid given
long-term stabil dialysi patient growth rate
keen assum recent weak treatment growth
like anomali industri data
date enough know sure either way
think model price overli optimist expect
basi point margin expans firm
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
dialysi franchis annual next five year
addit think intern busi final
contribut firm-wide profit sport mid-single-
digit ebitda margin
outlook market-impli
expect seem emb price improv
treatment growth annual margin declin
 busi profit contribut intern
oper us
assumpt appear pessimist believ
investor fairli compens
polici regulatori risk alway present
come dialysi
rule unconstitut district court
near-term impact fundament dec
dec judg reed connor northern district
texa issu rule effect declar patient
protect afford act
unconstitut assum littl chang
compani cover healthcar sector
near term rule like make way
appeal process surpris see
case third appear make front
 suprem court potenti timelin final
basi decis find root congress
elimin shared-respons financi penalti
accompani passag tax cut job act
late last year short judg connor found individu
mandat essenti insever provis
congress decis elimin enforc
tax penalti law render entireti
legisl unconstitut logic follow
 suprem court decis upheld
constitut congress power taxat
view healthcar provid sector at-risk
stem chang prevail healthcar
legisl whether chang individu coverag
roll-back medicaid expans higher uninsur
rate unequivoc equat pressur hospit margin
payer perspect trade-off littl less clear
although medicaid-focus insur like feel
bulk enrol loss
intend make chang moat rate fair
valu estim result decis continu
monitor case make way appel
court come month outcom timelin
uncertain make meaning chang
assumpt earli day addit wildcard
potenti legisl action muddi
ultim financi penalti carri
insur coverag set end jan
understand feder govern intend
maintain statu quo appeal process
insur alreadi lock rate propos
earliest like see potenti effect
rule premium polici offer slate
open enrol season
underli trend remain strong result
prop failur win industri
narrow-moat report third-quart result
track forecast firm specif
dialysi busi line view
intern ancillari servic segment came slightli
weaker anticip updat model
expect make chang per share fair valu
estim impli time
adjust ep ebitda forecast respect
perhap import event day california
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
voter reject proposit fairli wide margin --
littl vote side ballot
bake potenti impact prop
valuat given opinion likelihood
pass share ralli nearli day
turn quarter perform think could
somewhat disappoint first blush actual quit
strong surfac manag reduc outlook
full-year oper incom nearli million
driven discret item includ yearlong
opposit prop million one-tim stock
compens associ chang firm
retir polici back manag full-year
estim million total advocaci cost
would fall well ahead billion billion rang
manag provid outset year
think underli perform dialysi
continu well revenu per treatment line
expect same-facil volum growth clock
somewhat firm recent trend
line long-term forecast patient
growth nationwid intern declin clinic count
drove bulk shortfal versu forecast
think simpli time issu expect on-going
invest area time
deeper dive dialysi industri compani
valuat pleas see report titl dialysi remain
long believ kidney care industri one
healthcar provid market support durabl
econom moat attract return capit post
freseniu medic support view
firm carv uniqu competit posit
underpin cost advantag attain
largest compani space lend price
power negoti privat insur per-
treatment cost advantag allow firm treat
patient effici smaller provid
industri convolut reimburs structur
front-and-cent investor mind took closer
look came away confid outlook
compani industri price concern
weigh heavili valuat given focu
dialysi servic relianc market
freseniu fare bit better relev
intern presenc domin dialysi product
busi help diversifi oper ultim
believ critic product servic provid
freseniu ensur econom moat
endur long run think long-term orient
investor benefit acquir averag
busi discount valuat
follow recent weak freseniu trade
roughli discount fair valu estim
respect trade near time
adjust earn estim freseniu closer
time think market price too-pessimist
outlook industrywid price go forward help
treatment volum growth expect grow near
annual think firm narrow econom
moat protect investor return come year
deeper dive dialysi industri upcom
regulatori issu compani valuat pleas see
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
california veto repres win
would limit effect
charit assist program patient enrol
book commerci insur state focu
given outsiz market share california roughli
clinic state news share
recoup bulk recent under-perform tie
state assembl full
enforc would like low- mid-
single-digit hit firm-wide ebitda today ralli seem
reason estim passag implement
proposit could mid- high-single-digit hit
ebitda depend allow cost ultim
defin interpret said incorpor
effect base cash flow forecast
event odd worsen
governor veto result maintain fair valu
estim narrow-moat freseniu medic
per share per adr share respect
veto news repres small posit
dialysi industri think broader implic suggest
blanket legisl effort curb industri profit
like prove unsuccess vote prop come
nov think execut branch roadblock would like
make ballot measur difficult implement even
elect prop
industrywid price cap heavy-hand propos
believ would broadli harm patient access
freseniu smaller oper would like find
mani facil unprofit propos regul
expect freseniu ultim
navig type chang doubt
roughli clinic tie franchis would
prove success
affirm narrow-moat rate
take fresh look dialysi provid
freseniu medic maintain narrow
moat stabl trend rate firm modestli
rais fair valu estim compani
account cash flow receiv year date
tweak underli assumpt
fair valu estim increas per share
impli approxim time earn
ebitda estim freseniu case
bump fair valu estim local share eur
per share eur per share
adr impli multipl closer time
updat earn ebitda estim
dialysi industri focu much
critic last hand year think davita
freseniu carv defens econom moat
like endur come decad root
cost advantag deriv unpreced scale
think firm industri domin make like
earn excess return sharehold long run
freseniu look fairli valu us think
current present interest opportun
long-term investor approxim upsid
fair valu estim think investor would well
reward take advantag recent weak
view larg repres overreact market
spark passag legisl california
effect limit premium assist activ state
think stock subsequ tumbl fulli account
risk oper bill sign
law share price declin combin view
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
full implement law odd best
suggest us investor would well serv pick
share near current market valuat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
